Recent 8-K filings for LMRI
Highest-materiality recent filing
Lumexa Imaging closes IPO of 25M shares at $18.50, raises ~$462.5M
- IPO of 25,000,000 shares priced at $18.50 per share closed on Dec 12, 2025.
- Net proceeds to repay Barclays secured term loan and for working capital and capex.
-
Lumexa Imaging Q2 revenue up 5.1% to $264.2M; turns to net income of $2.7M
Q2 revenue $264.2M, up 5.1% YoY from $251.4M; system-wide growth 6.0%.
-
Lumexa Imaging enters $823M term loan and $250M revolver amendment, maturing 2032/2030
Secured term loan of ~$823M at SOFR+2.50% or Prime+1.50%, matures December 2032.
-
Lumexa Imaging elects Class I directors and ratifies PwC as auditor at 2026 annual meeting
Elected Lee Cooper, Brian Regan, and Caitlin Zulla as Class I directors; each to serve until 2029.
-
Lumexa Q1 rev $252.5M (+3.1%); net income $1.7M vs loss; reaffirms FY guidance
Consolidated revenues of $252.5M, up 3.1% YoY; net income $1.7M vs net loss of $7.7M.
-
Lumexa reiterates FY2026 guidance at investor meeting
Held meeting and site visit on April 8, 2026; reaffirmed previously disclosed full year 2026 guidance.
-
Lumexa Q4 rev $267.7M (+7.9%), Adj EBITDA $63.8M (+18.6%); reiterates 2026 guide
Q4 2025 consolidated revenues $267.7M (+7.9% YoY); net loss $28.7M vs $25.1M loss in Q4 2024.
-
Prelim Q4 2025 rev at least $261M (+5.2% YoY); adj. EBITDA at least $63M (+17% YoY).
-
Lumexa Imaging Chief Legal Officer Julie Szeker resigns effective March 13, 2026
Resignation not due to any disagreement with the company on operations, policies, or practices.
-
Lumexa refinances $825M term loan and $250M revolver; maturities extended to 2032 and 2030
$825M secured term loan facility (Refinancing Term Loan) priced at SOFR+3% or Prime+2%, maturing December 2032.
-
Lumexa Imaging closes IPO of 25M shares at $18.50, raises ~$462.5M
IPO of 25,000,000 shares priced at $18.50 per share closed on Dec 12, 2025.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.62 · Most common event earnings